Cancer Cell Biology

You have full text access to this OnlineOpen article

Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells

  1. Yuejuan Li1,
  2. Lingli Li1,
  3. Tracey J. Brown2,
  4. Paraskevi Heldin1,3,†,*

Article first published online: 21 FEB 2007

DOI: 10.1002/ijc.22550

Issue

International Journal of Cancer

International Journal of Cancer

Volume 120, Issue 12, pages 2557–2567, 15 June 2007

Additional Information

How to Cite

Li, Y., Li, L., Brown, T. J. and Heldin, P. (2007), Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells. Int. J. Cancer, 120: 2557–2567. doi: 10.1002/ijc.22550

Author Information

  1. 1

    Ludwig Institute for Cancer Research, Uppsala University, Box 595, Biomedical Center, Uppsala, Sweden

  2. 2

    Laboratory for Hyaluronan Research, Department of Biochemistry and Molecular Biology, Monash University, Clayton, Vic., Australia

  3. 3

    Department of Medical Biochemistry and Microbiology, Uppsala University, Box 595, Biomedical Center, Uppsala, Sweden

  1. †

    Fax: +46-18-16-04-20.

*Ludwig Institute for Cancer Research, Box 595, Uppsala University Biomedical Center, S-751 24 Uppsala, Sweden

  1. †

    Fax: +46-18-16-04-20.

Publication History

  1. Issue published online: 10 APR 2007
  2. Article first published online: 21 FEB 2007
  3. Manuscript Accepted: 28 NOV 2006
  4. Manuscript Received: 23 FEB 2006

Funded by

  • The Swedish Cancer Society
  • The Faculty of Medicine and Pharmacy, Uppsala University, Sweden

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (404K)

References

  • 1
    de la Torre M, Wells AF, Bergh J, Lindgren A. Localization of hyaluronan in normal breast tissue, radial scar, and tubular breast carcinoma. Hum Pathol 1993; 24: 1294–7.
  • 2
    Auvinen P, Tammi R, Parkkinen J, Tammi M, Agren U, Johansson R, Hirvikoski P, Eskelinen M, Kosma VM. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 2000; 156: 529–36.
  • 3
    Schor SL, Schor AM, Grey AM, Chen J, Rushton G, Grant ME, Ellis I. Mechanism of action of the migration stimulating factor produced by fetal and cancer patient fibroblasts: effect on hyaluronic and synthesis. In Vitro Cell Dev Biol 1989; 25: 737–46.
  • 4
    Culty M, Shizari M, Thompson EW, Underhill CB. Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: correlation with invasive potential. J Cell Physiol 1994; 160: 275–86.
    Direct Link:
  • 5
    Heldin P, de la Torre M, Ytterberg D, Bergh J. Differential synthesis and binding of hyaluronan by human breast cancer cell lines: relationship to hormone receptor status. Oncology Rep 1996; 3: 1011–6.
  • 6
    Assmann V, Marshall JF, Fieber C, Hofmann M, Hart IR. The human hyaluronan receptor RHAMM is expressed as an intracellular protein in breast cancer cells. J Cell Sci 1998; 111: 1685–94.
  • 7
    Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004; 4: 528–39.
  • 8
    Stern R, Csoka AB. Mammalian hyaluronidases. Available at www.glycoforum.gr.jp/science/hyaluronan/HA15/HA15E.html. 2000
  • 9
    Brinck J, Heldin P. Expression of recombinant hyaluronan synthase (HAS) isoforms in CHO cells reduces cell migration and cell surface CD44. Exp Cell Res 1999; 252: 342–51.
  • 10
    Camenisch TD, Schroeder JA, Bradley J, Klewer SE, McDonald JA. Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors. Nat Med 2002; 8: 850–5.
  • 11
    Lepperdinger G, Mullegger J, Kreil G. Hyal2–less active, but more versatile? Matrix Biol 2001; 20: 509–14.
  • 12
    Csoka AB, Frost GI, Stern R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 2001; 20: 499–508.
  • 13
    Stern R, Jedrzejas MJ. Hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev 2006; 106: 818–39.
  • 14
    Jacobson A, Rahmanian M, Rubin K, Heldin P. Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. Int J cancer 2002; 102: 212–9.
    Direct Link:
  • 15
    Simpson MA, Wilson CM, McCarthy JB. Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am J Pathol 2002; 161: 849–57.
  • 16
    Udabage L, Brownlee GR, Waltham M, Blick T, Walker EC, Heldin P, Nilsson SK, Thompson EW, Brown TJ. Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Res 2005; 6: 6139–50.
  • 17
    Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494–8.
  • 18
    Hannon GJ. RNA interference. Nature 2002; 418: 244–51.
  • 19
    Engel LW, Young NA, Tralka TS, Lippman ME, O'Brien SJ, Joyce MJ. Human breast carcinoma cells in culture: establishment and characteristics of three new cell lines. Cancer Res 1978; 38: 3352–64.
  • 20
    Davidson NE, Gelmann EP, Lippman ME, Dickson RB. Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1987; 1: 216–23.
  • 21
    Cailleau R, Young R, Olive' M, Reeves WJ. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 1974; 53: 661–7.
  • 22
    Hackett AJ, Smith HS, Springer EL, Owens RB, Nelson-Rees WA, Riggs JL, Gardner MB. Two syngeneic cell lines from human breast tissue: the aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst) cell lines. J Natl Cancer Inst 1977; 58: 1795–806.
  • 23
    Davidson NE, Lippman ME. Treatment of metastatic breast cancer. In: Diagnosis and management of breast cancer. LippmanME LichterAS and DanjorthDN (Eds), Philadelphia, Saunders, 1988. pp 375–406.
  • 24
    de la Torre M, Hao X-Y, Larsson R, Nygren P, Takashi T, Mannervik B, Bergh J. Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases. Anticancer Res 1993; 13: 1425–30.
  • 25
    Spicer AP, Augustine ML, McDonald JA. Molecular cloning and characterization of a putative mouse hyaluronan synthase. J Biol Chem 1996; 27: 23400–6.
  • 26
    Lekanne Deprez RH, Fijnvandraat AC, Ruijter JM, Moorman AF. Sensitivity and accuracy of quantitative real-time polymerase chain reaction using SYBR green I depends on cDNA synthesis conditions. Anal Biochem 2002; 307: 63–9.
  • 27
    Lebel L, Smith L, Risberg B, Laurent TC, Gerdin B. Increased lymphatic elimination of interstitial hyaluronan during E. coli sepsis in sheep. Am J Physiol 1989; 256: H1524–H1531.
  • 28
    Asplund T, Heldin P. Hyaluronan receptors are expressed on human malignant mesothelioma cells but not on normal mesothelial cells. Cancer Res 1994; 54: 4516–23.
  • 29
    Fraser JRE, Laurent TC, Pertoft H, Baxter E. Plasma clearance, tissue distribution and metabolism of hyaluronic acid injected intravenously in the rabbit. Biochem J 1981; 200: 415–24.
  • 30
    Culty M, Miyake K, Kincade PW, Silorski E, Butcher EC, Underhill CB. The hyaluronate receptor is a member of the CD44 (H-CAM) family of cell surface glycoproteins. J Cell Biol 1990; 111: 2765–74.
  • 31
    Jalkanen S, Bargatze RF, de los Toyos J, Butcher ECs. Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85–95 kDa glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J Cell Biol 1987; 105: 983–90.
  • 32
    Li Y, Heldin P. Hyaluronan production increases the malignant properties of mesothelioma cells. Br J Cancer 2001; 85: 600–7.
  • 33
    Lochter A, Srebrow A, Sympson CJ, Terracio N, Werb Z, Bissell MJ. Misregulation of stromelysin-1 expression in mouse mammary tumor cells accompanies acquisition of stromelysin-1-dependent invasive properties. J Biol Chem 1997; 272: 5007–15.
  • 34
    Thompson WW, Paik S, Brunner N, Sommers CL, Zugmaier G, Shima TB, Torri J, Donahue S, Lippman MC, Martin GR, Dickson RB. Association of increased basement membrane-invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Phys 1992; 150: 534–44.
    Direct Link:
  • 35
    Itano N, Atsumi F, Sawai T, Yamada Y, Miyaishi O, Senga T, Hamaguchi M, Kimata K. Abnormal accumulation of hyaluronan matrix diminishes contact inhibition of cell growth and promotes cell migration. Proc Natl Acad Sci USA 2002; 99: 3609–14.
  • 36
    Itano N, Sawai T, Atsumi F, Miyaishi O, Taniguchi S, Kannagi R, Hamaguchi M, Kimata K. Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. J Biol Chem 2004; 279: 18679–87.
  • 37
    Shin SI, Freedman VH, Risser R, Pollack R. Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci USA 1975; 72: 4435–9.
  • 38
    Udabage L, Brownlee GR, Nilsson SK, Brown TJ. The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res 2005; 310: 205–17.
  • 39
    Jacobson A, Brinck J, Briskin MJ, Spicer AP, Heldin P. Expression of human hyaluronan synthases in response to external stimuli. Biochem J 2000; 348: 29–35.
  • 40
    Zhang W, Watson CE, Liu C, Williams KJ, Werth VP. Glucocorticoids induce a near-total suppression of hyaluronan synthase mRNA in dermal fibroblasts and in osteoblasts: a molecular mechanism contributing to organ atrophy. Biochem J 2000; 349: 91–7.
  • 41
    Ward JA, Huang L, Guo H, Ghatak S, Toole BP. Perturbation of hyaluronan interactions inhibits malignant properties of glioma cells. Am J Pathol 2003; 162: 1403–9.
  • 42
    Ghatak S, Misra S, Toole BP. Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem 2005; 280: 8875–83.
  • 43
    Heldin P, Pertoft H. Synthesis and assembly of the hyaluronan-containing coats around normal human mesothelial cells. Exp Cell Res 1993; 208: 422–9.
  • 44
    Grammatikakis N, Grammatikakis A, Yoneda M, Yu Q, Banerjee SD, Toole BP. A novel glycosaminoglycan-binding protein is the vertebrate homologue of the cell cycle control protein, Cdc37. J Biol Chem 1995; 270: 16198–205.
  • 45
    Turley EA, Harrison R. RHAMM, a member of the hyaladherins. Available at http://glycoforum.gr.jp/science/hyaluronan/HA11/HA11E.html 1999.
  • 46
    Misra S, Toole BP, Ghatak S. Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem 2006; 281: 34936–34941.
  • 47
    Li L, Heldin C-H, Heldin P. Inhibition of PDGF-BB-induced receptor activation and fibroblast migration by hyaluronan activation of CD44. J Biol Chem 2006; 281: 26512–9.
  • 48
    Levine MD, Liotta LA, Stracke ML. Stimulation and regulation of tumor cell motility in invasion and metastasis. Exs 1995; 74: 157–79.
  • 49
    Jackson DG. The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. Trends Cardiovasc Med 2003; 13: 1–7.
  • 50
    Jackson DG, Prevo R, Clasper S, Banerji S. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol 2001; 22: 317–21.
View Full Article (HTML) Get PDF (404K)